

#### **TOR2A Antibody (Center) Blocking peptide** Synthetic peptide

Catalog # BP12178c

## Specification

# **TOR2A Antibody (Center) Blocking peptide - Product Information**

Primary Accession

#### <u>Q5JU69</u>

## **TOR2A Antibody (Center) Blocking peptide - Additional Information**

Gene ID 27433

**Other Names** Torsin-2A, Torsin family 2 member A, Torsin-related protein 1, TOR2A, TORP1

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage** Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions** This product is for research use only. Not for use in diagnostic or therapeutic procedures.

## **TOR2A Antibody (Center) Blocking peptide - Protein Information**

Name TOR2A

Synonyms TORP1

**Cellular Location** Endoplasmic reticulum lumen.

**Tissue Location** Isoform 1 is expressed ubiquitously, except in cardiac and endothelial tissues.

## **TOR2A Antibody (Center) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

Blocking Peptides

**TOR2A Antibody (Center) Blocking peptide - Images** 

**TOR2A Antibody (Center) Blocking peptide - Background** 



Salusins are multifunctional bioactive peptides discovered by bioinformatics analyses of a full-length cDNA library. Salusin alpha and salusin beta are related peptides of 28 and 20 amino acids that were recently characterized. These peptides are considered to be biosynthesized from preprosalusin, an alternative-splicing product of the torsion dystonia-related gene (TOR2A), after frameshift reading and digestion at dibasic amino acids. Salusin alpha has recently been shown to be involved in atherosclerosis; it potently suppresses acyl-CoA:cholesterol acyltransferase-1 which stores cholesterol ester converted from free cholesterol in macrophages, thereby reducing human macrophage foam cell formation.

## **TOR2A Antibody (Center) Blocking peptide - References**

O'Farrell, C.A., et al. Neuroscience 164(3):1127-1137(2009)Sato, K., et al. Peptides 29(12):2203-2207(2008)Watanabe, T., et al. Hypertens. Res. 31(3):463-468(2008)Wang, Z., et al. Eur. J. Pharmacol. 539(3):145-150(2006)Humphray, S.J., et al. Nature 429(6990):369-374(2004)